• slider-dummy-1.jpg
  • image3.jpg
  • image4.jpg

Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.

Learn more about our company
Visions and Values


FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

October 02, 2015

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the FDA has accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept).


Our people are our greatest resource. We are always looking for new colleagues to share in our commitment to make the world a healthier place.

Learn more about careers at Sandoz

Watch our videos to discover more about the world of Sandoz and the generics market.

Visit our video gallery to watch the latest episode



We have collected the most important and frequently asked questions about our business.

Visit our frequently asked questions page